Successful construction of eukaryotic plasmids containing HBV C genotype
HBV infection remains a major health problem in the world. Several data have revealed that lamivudine can efficiently promote the treatment of hepatitis B. However, a long-term treatment of lamivudine leads to the emergence of lamivudine-resistant mutants (YMDD mutants), which hampers the anti-HBV therapy. Therefore, researches related to HBV lamivudine-resistant mechanism has been of great significance. Up to date, many researches using eukaryotic plasmids containing either one type of HBV YMDD mutant or wild-type strains, without specification of HBV genotype, were reported. However, serial plasmids containing a specific HBV genotype, such as genotype C, and lamivudine-resistant sequences, which will allow systematic studies on the combined effects of HBV genotype together with lamivudine-resistant mutations, have not been reported.